Verastem, Inc. (VSTM) stock
VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.41−0.29 (-3.77%)
Close on Nov 17, 2026Market cap $671.08MP/E –Yield –
Verastem r&d expenses
Research and development expenses are spending on new products and technology.
Verastem's R&D Expenses for the twelve months ending Jun 30, 2026 was $140.22M. For fiscal 2025 it was $114.60M, up 40.9% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $114.60M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.60M | +40.9% |
| FY2024 | Dec 31, 2024 | $81.33M | +32.6% |
| FY2023 | Dec 31, 2023 | $61.36M | +21.4% |
| FY2022 | Dec 31, 2022 | $50.56M | +28.5% |
| FY2021 | Dec 31, 2021 | $39.35M | -4.9% |
| FY2020 | Dec 31, 2020 | $41.38M | -9.6% |
| FY2019 | Dec 31, 2019 | $45.78M | +4.9% |
| FY2018 | Dec 31, 2018 | $43.65M | -6.0% |
| FY2017 | Dec 31, 2017 | $46.42M | +134.7% |
| FY2016 | Dec 31, 2016 | $19.78M | -51.2% |
| FY2015 | Dec 31, 2015 | $40.57M | +14.4% |
| FY2014 | Dec 31, 2014 | $35.45M | +36.7% |
| FY2013 | Dec 31, 2013 | $25.93M | +19.4% |
| FY2012 | Dec 31, 2012 | $21.71M | +119.7% |
| FY2011 | Dec 31, 2011 | $9.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $41.34M | +66.8% |
| Q1 FY2026 | Mar 31, 2026 | $38.22M | +31.1% |
| Q4 FY2025 | Dec 31, 2025 | $31.67M | +52.2% |
| Q3 FY2025 | Sep 30, 2025 | $28.99M | -19.0% |
| Q2 FY2025 | Jun 30, 2025 | $24.79M | +10.2% |
| Q1 FY2025 | Mar 31, 2025 | $29.15M | +109.0% |
| Q4 FY2024 | Dec 31, 2024 | $20.81M | +61.4% |
| Q1 FY2024 | Jun 30, 2024 | $35.77M | +197.7% |
| Q4 FY2023 | Dec 31, 2023 | $22.50M | +109.5% |
| Q3 FY2023 | Sep 30, 2023 | $13.95M | +23.5% |
| Q2 FY2023 | Jun 30, 2023 | $12.89M | -13.4% |
| Q1 FY2023 | Mar 31, 2023 | $12.02M | -11.9% |
| Q4 FY2022 | Dec 31, 2022 | $10.74M | -5.8% |
| Q3 FY2022 | Sep 30, 2022 | $11.29M | +21.1% |
| Q2 FY2022 | Jun 30, 2022 | $14.89M | +53.0% |
| Q1 FY2022 | Mar 31, 2022 | $13.64M | +53.3% |
| Q4 FY2021 | Dec 31, 2021 | $11.40M | +12.2% |
| Q3 FY2021 | Sep 30, 2021 | $9.33M | -14.9% |
| Q2 FY2021 | Jun 30, 2021 | $9.73M | +4.1% |
| Q1 FY2021 | Mar 31, 2021 | $8.90M | -18.6% |
| Q4 FY2020 | Dec 31, 2020 | $10.15M | -18.5% |
| Q3 FY2020 | Sep 30, 2020 | $10.96M | -10.3% |
| Q2 FY2020 | Jun 30, 2020 | $9.34M | -17.6% |
| Q1 FY2020 | Mar 31, 2020 | $10.92M | +11.9% |
| Q4 FY2019 | Dec 31, 2019 | $12.46M | +42.1% |
| Q3 FY2019 | Sep 30, 2019 | $12.22M | +5.6% |
| Q2 FY2019 | Jun 30, 2019 | $11.35M | -8.4% |
| Q1 FY2019 | Mar 31, 2019 | $9.76M | -10.8% |
| Q4 FY2018 | Dec 31, 2018 | $8.76M | -22.1% |
| Q3 FY2018 | Sep 30, 2018 | $11.57M | -34.8% |
| Q2 FY2018 | Jun 30, 2018 | $12.38M | +36.9% |
| Q1 FY2018 | Mar 31, 2018 | $10.93M | +30.4% |
| Q4 FY2017 | Dec 31, 2017 | $11.25M | +63.3% |
| Q3 FY2017 | Sep 30, 2017 | $17.74M | +320.8% |
| Q2 FY2017 | Jun 30, 2017 | $9.04M | +101.3% |
| Q1 FY2017 | Mar 31, 2017 | $8.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.22M | – |
| Q2 FY2016 | Jun 30, 2016 | $4.49M | – |
See a number that looks wrong?